Study of new drug for relapsed or hard-to-treat multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that came back or did not respond to 1 to 3 prior treatments, including a proteasome inhibitor and lenalidomide.
- If you had only one prior treatment, you must have had no response or progression on lenalidomide.
- You have measurable signs of the disease in blood or urine tests.
- You are in generally good health with a performance status score of 0, 1, or 2 (able to care for yourself or up and about more than half the day).
- You have not received a therapy targeting BCMA (a protein on myeloma cells) before.
- You have not had allergic reactions to similar drugs and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
This trial tests a new drug (JNJ-79635322) combined with other treatments like daratumumab or pomalidomide for people with multiple myeloma. It aims to see if these combinations are safe and effective for newly diagnosed or previously treated patients.
This trial tests a new combination therapy (GR1803 plus an anti-CD38 monoclonal antibody) for people with multiple myeloma who have already tried lenalidomide and a proteasome inhibitor. It aims to see if the combination is safe and helps control the cancer.
This Phase 2 study tests a combination of medicines (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) for multiple myeloma that has come back or did not respond to prior treatment. It may help by better controlling the myeloma after standard therapies have failed.
This trial tests an experimental drug called JNJ-79635322 for people with multiple myeloma that has come back or hasn't responded to at least three previous treatments, including a PI, an IMiD, and a CD38-targeted antibody. The goal is to see if this new drug can help control the disease.
This trial tests different dosing schedules of three drugs (belantamab mafodotin, bortezomib, and dexamethasone) together to treat multiple myeloma that has come back or stopped responding to previous treatments. The goal is to find a dosing plan that works well and is tolerable for patients.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.